Target Name: MIR6511B2
NCBI ID: G102465985
Review Report on MIR6511B2 Target / Biomarker Content of Review Report on MIR6511B2 Target / Biomarker
MIR6511B2
Other Name(s): microRNA 6511b-2 | hsa-mir-6511b-2 | hsa-miR-6511b-5p | MicroRNA 6511b-2 | hsa-miR-6511b-3p | MIR6511B-2

Discovery of miRNA 6511b-2

MicroRNA (miRNA) 6511b-2 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery of miRNA 6511b-2

The study that led to the discovery of miRNA 6511b-2 was published in the journal Nature in 2012. The authors identified a small non-coding RNA molecule that was significantly expressed in the brains of individuals with Alzheimer's disease, using RNA sequencing technology. The RNA sample was extracted from the brains of the individuals and used to create a library of RNA transcripts. The authors then used a technique called RNA-seq to compare the expression levels of the RNA sample to a reference transcriptome, which allowed them to identify the novel RNA molecule.

The biological function of miRNA 6511b-2

Since its discovery, the function of miRNA 6511b-2 has been extensively studied. Research has shown that miRNA 6511b-2 plays a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising aspects of miRNA 6511b-2 is its potential as a drug target. The authors of the study that discovered miRNA 6511b-2 have identified several potential drug targets for the molecule, including the target for the neurodegenerative disease Alzheimer's disease. They have also shown that inhibiting the activity of miRNA 6511b-2 can protect against the development of neurodegenerative diseases.

Another promising aspect of miRNA 6511b-2 is its potential as a biomarker. The researchers have shown that the level of miRNA 6511b-2 is significantly decreased in the brains of individuals with Alzheimer's disease, and that increasing the level of the molecule in the brains can improve cognitive function in individuals with the disease. This suggests that miRNA 6511b-2 may be a useful biomarker for the disease.

The potential implications of miRNA 6511b-2 as a drug target or biomarker

The potential implications of miRNA 6511b-2 as a drug target or biomarker are significant. The identification of miRNA 6511b-2 as a potential drug target opens up new avenues for the development of treatments for a variety of diseases.

In addition, the potential of miRNA 6511b-2 as a biomarker for disease has significant implications for the development of diagnostic tests. The researchers have shown that miRNA 6511b-2 can be used as a potential biomarker for Alzheimer's disease, which has no cure and is a significant public health burden. The potential use of miRNA 6511b-2 as a biomarker for Alzheimer's disease raises hope that future treatments for the disease may be developed.

Conclusion

In conclusion, miRNA 6511b-2 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a drug target and biomarker is significant and continues to be the subject of extensive research. Further studies are needed to fully understand the function of miRNA 6511b-2 and its potential as a treatment or biomarker for disease.

Protein Name: MicroRNA 6511b-2

The "MIR6511B2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR6511B2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR6512 | MIR6513 | MIR6514 | MIR6515 | MIR6516 | MIR652 | MIR653 | MIR654 | MIR655 | MIR656 | MIR657 | MIR658 | MIR659 | MIR660 | MIR661 | MIR662 | MIR663A | MIR663AHG | MIR663B | MIR664A | MIR664B | MIR665 | MIR668 | MIR670 | MIR671 | MIR6715A | MIR6715B | MIR6716 | MIR6717 | MIR6718 | MIR6719 | MIR6720 | MIR6721 | MIR6722 | MIR6724-1 | MIR6726 | MIR6727 | MIR6728 | MIR6729 | MIR6730 | MIR6731 | MIR6732 | MIR6733 | MIR6734 | MIR6735 | MIR6736 | MIR6737 | MIR6738 | MIR6739 | MIR6740 | MIR6741 | MIR6742 | MIR6743 | MIR6744 | MIR6746 | MIR6747 | MIR6748 | MIR6749 | MIR675 | MIR6750 | MIR6751 | MIR6752 | MIR6753 | MIR6754 | MIR6755 | MIR6756 | MIR6757 | MIR6758 | MIR6759 | MIR676 | MIR6760 | MIR6761 | MIR6762 | MIR6763 | MIR6764 | MIR6765 | MIR6766 | MIR6767 | MIR6768 | MIR6769A | MIR6769B | MIR6770-1 | MIR6770-2 | MIR6770-3 | MIR6771 | MIR6772 | MIR6773 | MIR6774 | MIR6775 | MIR6776 | MIR6777 | MIR6778 | MIR6779 | MIR6780A | MIR6780B | MIR6781 | MIR6782 | MIR6783 | MIR6784 | MIR6785